Patricia K. Corey-Lisle, Ronald Peck, Pralay Mukhopadhyay, Lucinda Orsini, Shima Safikhani, Jill A. Bell, Gabriel Hortobagyi, Henri Roche, Pierfranco Conte and Dennis A. Revicki Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer Cancer 118
Article first published online: 19 MAY 2011 | DOI: 10.1002/cncr.26213
The current study evaluated the trade-off between quality and quantity of life using quality-adjusted time without symptoms or toxicity (Q-TWiST) outcomes for the combination of ixabepilone and capecitabine (cape) versus cape alone in patients with locally advanced/metastatic breast cancer. The Q-TWiST analysis was found to support a positive benefit-risk ratio for the combination of ixabepilone plus cape in patients with advanced/metastatic breast cancer that was refractory to anthracyclines and taxanes compared with cape monotherapy alone, despite the potential for added toxicities with combination therapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.